{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jelinek T"],"funding":["Cancer Research UK"],"pagination":["1383-1392"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9995102"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["41(7)"],"pubmed_abstract":["Purpose
Primary plasma cell leukemia (PCL) is the most aggressive monoclonal gammopathy. It was formerly characterized by ≥ 20% circulating plasma cells (CTCs) until 2021, when this threshold was decreased to ≥ 5%. We hypothesized that primary PCL is not a separate clinical entity, but rather that it represents ultra-high-risk multiple myeloma (MM) characterized by elevated CTC levels.Methods
We assessed the levels of CTCs by multiparameter flow cytometry in 395 patients with newly diagnosed transplant-ineligible MM to establish a cutoff for CTCs that identifies the patients with ultra-high-risk PCL-like MM. We tested the cutoff on 185 transplant-eligible patients with MM and further validated on an independent cohort of 280 transplant-ineligible patients treated in the GEM"],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pubmed_title":["More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma."],"pmcid":["PMC9995102"],"funding_grant_id":["C355/A26819"],"pubmed_authors":["Pospisilova L","Hajek R","Hrdinka M","Mateos MV","Simicek M","Anilkumar Sithara A","Cedena MT","Kapustova V","Puig N","Radocha J","Jelinek T","Stork M","Popkova T","Venglar O","Garces JJ","Jurczyszyn A","Muronova L","Castillo JJ","Chyra Z","San-Miguel JF","Rihova L","Penka M","Paiva B","Knechtova Z","Bezdekova R","Zihala D","Sevcikova T","Sevcikova S","Polackova P","Pour L"],"additional_accession":[]},"is_claimable":false,"name":"More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma.","description":"Purpose
Primary plasma cell leukemia (PCL) is the most aggressive monoclonal gammopathy. It was formerly characterized by ≥ 20% circulating plasma cells (CTCs) until 2021, when this threshold was decreased to ≥ 5%. We hypothesized that primary PCL is not a separate clinical entity, but rather that it represents ultra-high-risk multiple myeloma (MM) characterized by elevated CTC levels.Methods
We assessed the levels of CTCs by multiparameter flow cytometry in 395 patients with newly diagnosed transplant-ineligible MM to establish a cutoff for CTCs that identifies the patients with ultra-high-risk PCL-like MM. We tested the cutoff on 185 transplant-eligible patients with MM and further validated on an independent cohort of 280 transplant-ineligible patients treated in the GEM","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2025-04-19T02:38:40.462Z","creation":"2025-02-19T04:43:49.191Z"},"accession":"S-EPMC9995102","cross_references":{"pubmed":["36315921"],"doi":["10.1200/JCO.22.01226"]}}